» Articles » PMID: 22004872

[18F]fluorothymidine PET Imaging in the Diagnosis of Leptomeningeal Involvement with Diffuse Large B-cell Lymphoma

Overview
Journal Cancer Imaging
Publisher Springer Nature
Specialties Oncology
Radiology
Date 2011 Oct 19
PMID 22004872
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The diagnosis of leptomeningeal carcinomatosis remains difficult despite improvement in central nervous system (CNS) imaging and cytologic examination of the cerebral spinal fluid. False-negative results are common, providing obstacles in assessing both prophylactic and therapeutic efforts. As a result of increased survival of patients with a variety of systemic neoplasms it is likely that central nervous involvement will need to be addressed more often. This article presents a patient with a diffuse large B-cell lymphoma with polymorphic features. Imaging using 18F-labeled fluorodeoxythymidine (FLT) proved useful in demonstrating both parenchymal and leptomeningeal CNS involvement. The potential for FLT to identify proliferative tissue may make it uniquely suitable for detection of CNS malignant disease.

Citing Articles

Applications of PET in Diagnosis and Prognosis of Leukemia.

Zhao Z, Hu Y, Li J, Zhou Y, Zhang B, Deng S Technol Cancer Res Treat. 2020; 19:1533033820956993.

PMID: 32875963 PMC: 7476341. DOI: 10.1177/1533033820956993.


Imaging haemopoietic stem cells and microenvironment dynamics through transplantation.

Williams K, Holter Chakrabarty J Lancet Haematol. 2020; 7(3):e259-e269.

PMID: 32109406 PMC: 7820939. DOI: 10.1016/S2352-3026(20)30003-X.


In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[F]fluorothymidine PET/MRI.

Bashir A, Binderup T, Vestergaard M, Broholm H, Marner L, Ziebell M Eur J Nucl Med Mol Imaging. 2020; 47(6):1496-1509.

PMID: 32047966 DOI: 10.1007/s00259-020-04704-2.


Nuclear oncology in Cancer Imaging 2011.

Miles K Cancer Imaging. 2012; 12:185-6.

PMID: 22750163 PMC: 3392780. DOI: 10.1102/1470-7330.2012.0025.

References
1.
Chamberlain M . Natural History of CNS Relapse in Aggressive Non-Hodgkin's Lymphoma: What Have We Learned?. J Clin Oncol. 2009; 27(21):e26. DOI: 10.1200/JCO.2009.22.0608. View

2.
Quijano S, Lopez A, Sancho J, Panizo C, Deben G, Castilla C . Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009; 27(9):1462-9. DOI: 10.1200/JCO.2008.17.7089. View

3.
Grisariu S, Avni B, Batchelor T, van den Bent M, Bokstein F, Schiff D . Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2010; 115(24):5005-11. PMC: 3710441. DOI: 10.1182/blood-2009-12-258210. View

4.
DeAngelis L . Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998; 38(2-3):245-52. DOI: 10.1023/a:1005956925637. View

5.
Walker J . Diagnosis and management of leptomeningeal disease. Clin J Oncol Nurs. 2009; 13(4):384-7. DOI: 10.1188/09.CJON.384-387. View